KoreaMed Synapse

Journal List > J Rheum Dis > v.24(3) > 1064315

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Min: Is Urinary Tumor Necrosis Factor-like Weak Inducer of Apoptosis a Biomarker of Lupus Nephritis?

Editorial

J Rheum Dis 2017;24(3):125-126.

Published online: 31 October 2017

DOI: https://doi.org/10.4078/jrd.2017.24.3.125

Is Urinary Tumor Necrosis Factor-like Weak Inducer of Apoptosis a Biomarker of Lupus Nephritis?

Jun-Ki Min

Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea

Corresponding to: Jun-Ki Min, Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, 327 Sosa-ro, Wonmi-gu, Bucheon 14647, Korea. E-mail: min6403@catholic.ac.kr

Received 26 May 2017 Accepted 29 May 2017

Copyright © 2017 The Korean College of Rheumatology

This is a Open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999; 10:413–24.

2. Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol. 2015; 11:46–61.

3. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012; 27:3248–54.

4. Li Y, Tucci M, Narain S, Barnes EV, Sobel ES, Segal MS, et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev. 2006; 5:383–8.

5. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 2004; 50:1709–20.

6. Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis. 2013; 5:210–33.

7. Misra R, Gupta R. Biomarkers in lupus nephritis. Int J Rheum Dis. 2015; 18:219–32.

8. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002; 27:19–26.

9. Wajant H. The TWEAK-Fn14 system as a potential drug target. Br J Pharmacol. 2013; 170:748–64.

10. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008; 7:411–25.

11. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005; 123:931–44.

12. Baxter FO, Came PJ, Abell K, Kedjouar B, Huth M, Rajewsky K, et al. IKKbeta/2 induces TWEAK and apoptosis in mam-mary epithelial cells. Development. 2006; 133:3485–94.

13. Xu WD, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res. 2016; 64:44–50.

14. Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol. 2015; 26:1053–70.

15. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol. 2006; 176:1889–98.

16. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun. 2006; 27:242–50.

17. Lee YH, Song GG. Urinary tumor necrosis factor-like weak inducer of apoptosis as a biomarker for lupus nephritis: a meta-analysis. J Rheum Dis. 2017; 24:85–92.

18. Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012; 64:2687–97.

TOOLS

Similar articles